These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 9727758)
21. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Greally P; Whitaker P; Peckham D Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602 [TBL] [Abstract][Full Text] [Related]
22. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. Hadjiliadis D; Steele MP; Chaparro C; Singer LG; Waddell TK; Hutcheon MA; Davis RD; Tullis DE; Palmer SM; Keshavjee S J Heart Lung Transplant; 2007 Aug; 26(8):834-8. PubMed ID: 17692788 [TBL] [Abstract][Full Text] [Related]
23. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Johansen HK; Nørregaard L; Gøtzsche PC; Pressler T; Koch C; Høiby N Pediatr Pulmonol; 2004 May; 37(5):427-32. PubMed ID: 15095326 [TBL] [Abstract][Full Text] [Related]
24. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. Campana S; Taccetti G; Ravenni N; Masi I; Audino S; Sisi B; Repetto T; Döring G; de Martino M J Cyst Fibros; 2004 Aug; 3(3):159-63. PubMed ID: 15463902 [TBL] [Abstract][Full Text] [Related]
26. Risk factors for Burkholderia cepacia complex colonization and infection among patients with cystic fibrosis. Walsh NM; Casano AA; Manangan LP; Sinkowitz-Cochran RL; Jarvis WR J Pediatr; 2002 Oct; 141(4):512-7. PubMed ID: 12378190 [TBL] [Abstract][Full Text] [Related]
27. Pathophysiology and management of pulmonary infections in cystic fibrosis. Gibson RL; Burns JL; Ramsey BW Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458 [TBL] [Abstract][Full Text] [Related]
28. Burkholderia (Pseudomonas) cepacia and cystic fibrosis: the epidemiology in Belgium. Revets H; Vandamme P; Van Zeebroeck A; De Boeck K; Struelens MJ; Verhaegen J; Ursi JP; Verschraegen G; Franckx H; Malfroot A; Dab I; Lauwers S Acta Clin Belg; 1996; 51(4):222-30. PubMed ID: 8858887 [TBL] [Abstract][Full Text] [Related]
29. Cystic fibrosis infections: treatment strategies and prospects. George AM; Jones PM; Middleton PG FEMS Microbiol Lett; 2009 Nov; 300(2):153-64. PubMed ID: 19674113 [TBL] [Abstract][Full Text] [Related]
30. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Rosenfeld M; Ramsey BW; Gibson RL Curr Opin Pulm Med; 2003 Nov; 9(6):492-7. PubMed ID: 14534401 [TBL] [Abstract][Full Text] [Related]
31. In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis. Kurlandsky LE; Fader RC Pediatr Pulmonol; 2000 Mar; 29(3):210-2. PubMed ID: 10686042 [TBL] [Abstract][Full Text] [Related]
32. Burkholderia cepacia complex in cystic fibrosis in a Brazilian reference center. Dentini P; Marson FAL; Bonadia LC; Bertuzzo CS; Ribeiro AF; Levy CE; Ribeiro JD Med Microbiol Immunol; 2017 Dec; 206(6):447-461. PubMed ID: 28965239 [TBL] [Abstract][Full Text] [Related]
33. Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa. Hendry J; Elborn JS; Nixon L; Shale DJ; Webb AK Eur Respir J; 1999 Aug; 14(2):435-8. PubMed ID: 10515426 [TBL] [Abstract][Full Text] [Related]
34. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Döring G; Jansen S; Noll H; Grupp H; Frank F; Botzenhart K; Magdorf K; Wahn U Pediatr Pulmonol; 1996 Feb; 21(2):90-100. PubMed ID: 8882212 [TBL] [Abstract][Full Text] [Related]
35. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Kosorok MR; Zeng L; West SE; Rock MJ; Splaingard ML; Laxova A; Green CG; Collins J; Farrell PM Pediatr Pulmonol; 2001 Oct; 32(4):277-87. PubMed ID: 11568988 [TBL] [Abstract][Full Text] [Related]
36. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. Hansen CR; Pressler T; Høiby N J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078 [TBL] [Abstract][Full Text] [Related]
37. Low incidence of pulmonary Pseudomonas cepacia infection in Danish cystic fibrosis patients. Nir M; Johansen HK; Høiby N Acta Paediatr; 1992 Dec; 81(12):1042-3. PubMed ID: 1283959 [No Abstract] [Full Text] [Related]
38. [Isolation frequency of Burkholderia cepacia from cystic fibrosis patients]. Ocak F; Gözalan A; Ozçelik U; Anadol D; Kiper N; Aktepe OC; Göçmen A; Esen B Mikrobiyol Bul; 2002 Jan; 36(1):1-10. PubMed ID: 12476760 [TBL] [Abstract][Full Text] [Related]
39. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. Li Z; Kosorok MR; Farrell PM; Laxova A; West SE; Green CG; Collins J; Rock MJ; Splaingard ML JAMA; 2005 Feb; 293(5):581-8. PubMed ID: 15687313 [TBL] [Abstract][Full Text] [Related]